Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Reports Phase III Success of PD-1 in Lung Cancer Patients

publication date: Jan 13, 2020

Suzhou Innovent Biologics (HK: 01801) reported its PD-1 drug met a predefined progression-free survival endpoint in a China Phase III non-small cell lung cancer trial. Innovent said the data was consistent with an earlier stage trial. One year ago, Innovent announced Tyvyt® produced an 68% objective response rate and an 11.4 month median progression-free survival in a similar Phase I test. In the Phase III trial, Innovent tested Tyvyt® in combination with chemotherapy and platinum in first-line nonsquamous non-small cell lung cancer, without sensitive EGFR mutation or ALK rearrangement. More details...

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China